^
    Apply
    Olinvacimab With Pembrolizumab in Patients With mTNBC (KEYNOTE-C14) (NCT04986852)
    Phase 2
    PharmAbcine
    Recruiting
    Last update posted :
    11/16/2023
    Initiation :
    09/30/2021
    Primary completion :
    02/28/2025
    Completion :
    08/30/2026
    HER-2 • ER • PGR • CD4
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)
    TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer (NCT03720431)
    Phase 1b
    PharmAbcine
    Active, not recruiting
    Last update posted :
    08/17/2022
    Initiation :
    01/03/2019
    Primary completion :
    03/18/2020
    Completion :
    10/26/2022
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • olinvacimab (TTAC-0001)